Ontology highlight
ABSTRACT:
PROVIDER: PRJEB42149 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR5006080_1.fastq.gz | Fastqsanger.gz | |||
| ERR5006080_2.fastq.gz | Fastqsanger.gz | |||
| ERR5006090_1.fastq.gz | Fastqsanger.gz | |||
| ERR5006090_2.fastq.gz | Fastqsanger.gz | |||
| ERR5006100_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 68 |
Similar Datasets
Project description:Probiotic therapy supports estrogen metabolism in postmenopausal women
| PRJNA1303383 | ENA
Project description:Modification of Gene Expression of Skeletal Muscle in Response to postmenopause with or without Hormone Replacement Therapy. Even though menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood. We have used a randomized double-blinded study design together with an explorative microarray experiment to characterize possible effects of continuous, combined HRT and estrogen deprivation on the skeletal muscle of fifteen early postmenopausal women from which 10 used HRT and 5 used placebo for 12-months in a douple-blinded design. Keywords: time course analysis from HRT users and non-users comparison of gene expression in skeletal muscle of healthy postmenopausel women using HRT (n=10) vs not-using HRT (n=5)
2007-11-12 | E-GEOD-6348 | biostudies-arrayexpress
Project description:Modification of Gene Expression of Skeletal Muscle in Response to postmenopause with or without Hormone Replacement Therapy. Even though menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood. We have used a randomized double-blinded study design together with an explorative microarray experiment to characterize possible effects of continuous, combined HRT and estrogen deprivation on the skeletal muscle of fifteen early postmenopausal women from which 10 used HRT and 5 used placebo for 12-months in a douple-blinded design. Keywords: time course analysis from HRT users and non-users
2007-11-12 | GSE6348 | GEO
Project description:Pre-exposure chemoprophylaxis using antiretroviral agents is a promising strategy for the prevention of sexual HIV transmission in women. Molecular transporters in the human vaginal tract may play a pivotal role in determining drug disposition and, consequently, pharmacodynamic outcomes in these efforts. Little is known, however, on the expression of these transporters in vaginal tissues, representing a critical knowledge gap. Our study analyzed the genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women undergoing gynecologic surgeries. The genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women (20-56 years old) undergoing gynecologic surgeries was measured.
2014-01-29 | E-GEOD-49892 | biostudies-arrayexpress
Project description:Pelvic organ prolapse (POP), affecting up to 50% of elderly women, disrupts vaginal microbial homeostasis, yet the impact of first-line pessary therapy on microbiome dynamics remains poorly characterized. This prospective cohort study employed metagenomic sequencing and clinical metrics to longitudinally analyze vaginal microbiota in 41 postmenopausal POP-III/IV patients undergoing pessary therapy, compared to surgical intervention and healthy controls. Pre-treatment POP patients exhibited dysbiosis marked by elevated aerobic pathogen (e.g., Gardnerella vaginalis, Streptococcus agalactiae) and bacterial vaginosis (BV)-associated taxa, which may correlating with anatomical oxygen exposure. pessary therapy drove time-dependent microbial stabilization: within 3 months, Lactobacillus crispatus and Lactobacillus jensenii reclaimed dominance (∼90% abundance), suppressing BV-associated genera (Corynebacterium spp., Streptococcus spp.), while surgery failed to improve dysbiosis. Patients developing pessary-associated ulcers showed distinct enrichment of G. vaginalis, S. anginosus, and Atopobium vaginae, enabling a predictive model (AUC: 0.848) for complication risk. Metabolomic profiling revealed pessary-induced activation of pentose phosphate and glycerophospholipid pathways, aligning with microbial recovery. These findings establish pessary therapy as a dual restorative intervention—anatomically and microbially—while identifying actionable biomarkers for complication prevention. Our work advocates integrating microbiome-guided strategies into POP management to optimize therapeutic outcomes.
2025-07-16 | MTBLS12722 | MetaboLights
Project description:Breast cancer risk continues to increase post menopause. Anti-estrogen therapies are available to prevent postmenopausal breast cancer in high-risk women. However, their adverse effects have reduced acceptability and overall success in cancer prevention. Natural products such as hops (Humulus lupulus) and three pharmacopeial licorice (Glycyrrhiza) species have demonstrated estrogenic and chemopreventive properties, but little is known regarding their effects on aromatase expression and activity as well as pro-proliferation pathways in human breast tissue. We show that Gycyrrhiza inflata (GI) has the highest aromatase inhibition potency among these plant extracts. Moreover, phytoestrogens such as liquiritigenin which is common in all licorice species have potent aromatase inhibitory activity, which is further supported by computational docking of their structures in the binding pocket of aromatase. In addition, GI extract and liquiritigenin suppress aromatase expression in the breast tissue of high-risk postmenopausal women. Although liquiritigenin has estrogenic effects in vitro, with preferential activity through estrogen receptor (ER)-β, it reduces estradiol-induced uterine growth in vivo. It downregulates RNA translation, protein biosynthesis, and metabolism in high-risk women’s breast tissue. Finally, it reduces the rate of MCF-7 cell proliferation, with repeated dosing. Collectively, these data suggest that liquiritigenin has breast cancer prevention potential for high-risk postmenopausal women. We then performed gene expression profiling analysis using data obtained from RNA-seq of 4 different cells at two time points.
2023-08-30 | GSE223524 | GEO
Project description:The onset of menopause is accompanied by a dramatic increase in reported symptoms of vaginal dryness, soreness, irritation or itching, pain with intercourse and bleeding after intercourse. Collectively these affect 25-50% of women of post-menopausal age and significantly impact their quality of life. To examine how gene expression differs between these groups, surface vaginal epithelial cells were collected from postmenopausal women suffering from vaginal dryness and appropriate controls not suffering from dryness. Affymetrix GeneChip Human 1.0 ST microarrays were performed on RNA isolated from ten participants.
2011-11-12 | GSE26761 | GEO
Project description:The onset of menopause is accompanied by a dramatic increase in reported symptoms of vaginal dryness, soreness, irritation or itching, pain with intercourse and bleeding after intercourse. Collectively these affect 25-50% of women of post-menopausal age and significantly impact their quality of life. To examine how gene expression differs between these groups, surface vaginal epithelial cells were collected from postmenopausal women suffering from vaginal dryness and appropriate controls not suffering from dryness. Affymetrix GeneChip Human 1.0 ST microarrays were performed on RNA isolated from ten participants. Suitable RNA was extracted from ten participants which were classified into two groups, the dryness and control groups, based on diagnosis of dryness by a nurse during gynecoligical examination.
2011-11-12 | E-GEOD-26761 | biostudies-arrayexpress
Project description:<p><strong>INTRODUCTION:</strong> Postmenopausal hormone use is linked to several health outcomes and the risk associated with some may differ depending on whether estrogen is used alone or in combination with progestin.</p><p><strong>OBJECTIVE:</strong> Metabolomic analyses of postmenopausal hormone use and differences between hormone regimes was carried out to identify metabolites associated with each type of hormone treatment.</p><p><strong>METHODS:</strong> Untargeted metabolomics analysis was carried out on serum from 1,336 women enrolled in the Cancer Prevention II Nutrition Cohort. Levels of 781 named metabolites were compared between 667 nonusers with 332 estrogen-only and with 337 estrogen plus progestin users using linear regression. Metabolite levels were also compared between estrogen-only and estrogen plus progestin users.</p><p><strong>RESULTS:</strong> Compared to nonusers, 276 metabolites were statistically significantly (P<6.40 x 10-5) associated with estrogen-only use and 222 were associated with estrogen plus progestin use. The metabolites associated with both types of hormones included numerous lipids, acyl carnitines, and amino acids as well as the thyroid hormone thyroxine and the oncometabolite fumarate. The 65 metabolites that differed significantly between estrogen-only and estrogen plus progestin users included 19 steroids and 12 lipids that contained the bioactive fatty acid arachidonic acid.</p><p><strong>CONCLUSIONS:</strong> These findings suggest that postmenopausal hormone use influences metabolic pathways linked to a variety of cellular processes, including the regulation of metabolism and stress responses, energy production, and inflammation. The differential association of numerous lipids that could influence cellular signaling suggests that differences in signal transduction may contribute to the disparate risks for some diseases between estrogen-only and estrogen plus progestin users.</p>
2019-06-02 | MTBLS136 | MetaboLights